Article ID Journal Published Year Pages File Type
5698647 Clinical Oncology 2014 9 Pages PDF
Abstract
Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial
Authors
, , , , , , , , ,